Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Phase 1 Clinical Safety, Pharmacokinetics (PK), and Activity of Apilimod Dimesylate (LAM-002A), a First-in-Class Inhibitor of Phosphatidylinositol-3-Phosphate 5-Kinase (PIKfyve), in Patients with Relapsed or Refractory B-Cell Malignancies

Wael A Harb, MD, Catherine S Diefenbach, MD, Nehal Lakhani, MD PhD, Sarah C Rutherford, MD, Marshall T Schreeder, MD, Stephen M Ansell, MD PhD, Taimur Sher, MD, David M Aboulafia, MD, Jonathon B Cohen, MDMS, Darrell Nix, BS, PhD, Sean Landrette, PhD, Kate Flanders, BS, Langdon L Miller, MD, Henri Lichenstein, PhD, Jeremy S. Abramson, MD MMSc

Blood (2017) 130 (Supplement 1): 4119.

https://doi.org/10.1182/blood.V130.Suppl_1.4119.4119

Published: 2017

Journal Articles

Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, Combines Safely with Pomalidomide and Dexamethasone and Shows Promosing Early Results in Relapsed-and-Refractory Myeloma (ACE-MM-102 Study)

Noopur S. Raje, MD, William Bensinger, MD, Craig E. Cole, MD, Sagar Lonial, MD, Sundar Jagannath, MD, Carlos E. Arce-Lara, MD, Jason Valent, MD, Ashley E Rosko, MD, Wael A. Harb, MD, Irwindeep Sandhu, MD, Nizar J Bahlis, MD, Donna Reece, Evangelos Terpos, MD, Jeffrey Supko, PhD, David Tamang, PhD, Simon S Jones, PhD, Catherine Wheeler, MD, Robert J Markelewicz, Jr., MD, Paul G. Richardson

Blood (2015) 126 (23): 4228.

https://doi.org/10.1182/blood.V126.23.4228.4228

Published: 2015

Journal Articles

Results of First in Human (FIH) Phase 1 Pharmacokinetic (PK) Guided Dose-Escalation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine in Subjects with Myelodysplastic Syndromes (MDS)

Michael R. Savona, MD, Olatoyosi Odenike, MD, Philip C. Amrein, MD, David P. Steensma, MD, Wael A. Harb, MD, Amy E. DeZern, MD MHS, Laura C. Michaelis, MD, Stefan Faderl, MD, James N. Lowder, MD, Pietro Taverna, PhD, Aram Oganesian, PhD, Richa Dua, PharmD, Roya Nawabi, Mohammad Azab, MD, Guillermo Garcia-Manero, MD

Blood (2015) 126 (23): 1683.

https://doi.org/10.1182/blood.V126.23.1683.1683

Published: 2015

Journal Articles

Preliminary Results from a Phase 1/2, Open-Label, Dose-Escalation Clinical Trial of IMO-8400 in Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia

Sheeba K. Thomas, MD, Wael A. Harb, MD, Joseph Thaddeus Beck, MD, Gabrail Nashat, MD, M. Lia Palomba, MD, Stephen M Ansell, MD PhD, Herbert Eradat, MD, Edward N. Libby, III, MD, Ranjana H Advani, MD, Julio Hajdenberg, MD, Leonard T Heffner, MD, James Hoffman, MD, David H. Vesole, MD, Lindsey Simov, Nancy Wyant, Julie Brevard, MPH, James O'Leary, MD, Sudhir Agrawal, D.Phil

Blood (2015) 126 (23): 1540.

https://doi.org/10.1182/blood.V126.23.1540.1540

Published: 2015

Journal Articles

The BCL2 Targeted Deoxyribonucleic Acid Inhibitor (DNAi) PNT2258 Is Active in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma

Wael A. Harb, MD, Nehal Lakhani, MD PhD, Ana Logsdon, LPN, Clinical Research Coordinator, Mary Steigelman, RN, Heidi Smith-Green, BSN, RN, Shari Gaylor, RN, Wendi Rodrigueza, PhD, Michael Woolliscroft, BA, MBA, Mina Sooch, BS, MBA, Richard A. Messmann, MD MHS, MSc, Ayad Al-Katib, MD FACP

Blood (2014) 124 (21): 1716.

https://doi.org/10.1182/blood.V124.21.1716.1716

Published: 2014

Journal Articles

Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Jennifer R. Brown, MD, PhD, Wael A. Harb, MD, Brian T. Hill, MD, PhD, Janice Gabrilove, MD, Jeff P. Sharman, MD, Marshall T. Schreeder, MD, MPH, Paul M. Barr, MD, James M. Foran, MD, Thomas P. Miller, MD, Jan A. Burger, MD, PhD, Kevin R. Kelly, MD, PhD, Daruka Mahadevan, MD, PhD, Shuo Ma, MD, PhD, Evelyn Barnett, Jeffrey Marine, Pilar Nava-Parada, Ada Azaryan, Jay Mei, MD, Thomas J. Kipps, MD, PhD

Blood (2013) 122 (21): 1630.

https://doi.org/10.1182/blood.V122.21.1630.1630

Published: 2013

Journal Articles

The BCL2 Targeted Deoxyribonucleic Acid Inhibitor (DNAi) PNT2258 Is Active In Patients With Relapsed Or Refractory Non-Hodgkin’s Lymphoma

Wael A. Harb, MD, Nehal Lakhani, MD, PhD, Ana Logsdon, LPN, Clinical Research Coordinator, Mary Steigelman, RN, Heidi Smith-Green, BSN, RN, Shari Gaylor, RN, Michael Woolliscroft, BA, MBA, Wendi Rodrigueza, Ph.D., Mina Sooch, BS, MBA, Richard A. Messmann, MD, MHS, MSc, Ayad Al-Katib, MD, FACP

Blood (2013) 122 (21): 88.

https://doi.org/10.1182/blood.V122.21.88.88

Published: 2013

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Phase 1 Clinical Safety, Pharmacokinetics (PK), and Activity of Apilimod Dimesylate (LAM-002A), a First-in-Class Inhibitor of Phosphatidylinositol-3-Phosphate 5-Kinase (PIKfyve), in Patients with Relapsed or Refractory B-Cell Malignancies

Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, Combines Safely with Pomalidomide and Dexamethasone and Shows Promosing Early Results in Relapsed-and-Refractory Myeloma (ACE-MM-102 Study)

Results of First in Human (FIH) Phase 1 Pharmacokinetic (PK) Guided Dose-Escalation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine in Subjects with Myelodysplastic Syndromes (MDS)

Preliminary Results from a Phase 1/2, Open-Label, Dose-Escalation Clinical Trial of IMO-8400 in Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia

The BCL2 Targeted Deoxyribonucleic Acid Inhibitor (DNAi) PNT2258 Is Active in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma

Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

The BCL2 Targeted Deoxyribonucleic Acid Inhibitor (DNAi) PNT2258 Is Active In Patients With Relapsed Or Refractory Non-Hodgkin’s Lymphoma

Email alerts

ASH Publications

American Society of Hematology